Anti-DNA antibodies: aspects of structure and pathogenicity.
about
Is closer linkage between systemic lupus erythematosus and anti-double-stranded DNA antibodies a desirable and attainable goal?Immunological aspects in chronic lymphocytic leukemia (CLL) developmentImpact of DNA Hairpin Folding Energetics on Antibody–ssDNA AssociationCellular internalization mechanism and intracellular trafficking of filamentous M13 phages displaying a cell-penetrating transbody and TAT peptideSpecific cross-reaction of anti-dsDNA antibody with platelet integrin GPIIIa49-66Probing substituent effects in aryl-aryl interactions using stereoselective Diels-Alder cycloadditions.Design of targeted B cell killing agents.Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice.The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.A mouse variable gene fragment binds to DNA independently of the BCR context: a possible role for immature B-cell repertoire establishment.A ssDNA Aptamer That Blocks the Function of the Anti-FLAG M2 AntibodyAn entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells.Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.The origin and properties of extracellular DNA: from PAMP to DAMP.Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence.A novel DNA/histone H4 peptide complex detects autoantibodies in systemic lupus erythematosus sera.Chromatin as a target antigen in human and murine lupus nephritisAntibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality.Lupus nephritis: enigmas, conflicting models and an emerging concept.The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved.An anti-DNA antibody prefers damaged dsDNA over native.Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases.Understanding mechanisms of hypertension in systemic lupus erythematosus.Antigen receptor stereotypy in chronic lymphocytic leukemia.Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational studyGeneration, characterization, and docking studies of DNA-hydrolyzing recombinant F(ab) antibodies.B Cell Anergy Modulated by TLR1/2 and the miR-17∼92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4.Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.Autoantibodies in SLE: Specificities, Isotypes and ReceptorsPathogenic effect of a cell-penetrating anti-dsDNA autoantibody through p38 signaling pathway and pro-inflammatory cytokine stimulation in mesangial cellsDevelopment of single-chain Fv of antibody to DNA as intracellular delivery vehicleAntibody Epitope Specificity for dsDNA Phosphate Backbone Is an Intrinsic Property of the Heavy Chain Variable Germline Gene Segment Used
P2860
Q24804411-FB098FC8-7BB7-4C71-997B-0AF7A32B48B6Q26865940-B82E475C-9960-4E63-B08B-323889D03DDDQ27649115-E9B3E18F-93E1-4DB9-902B-E85E46CAF27CQ28484366-1923A875-A361-41E3-925D-D1E65D64013EQ33391806-41D51241-1E2C-4A4F-B477-7F93993B25CAQ33729135-91B1B529-D289-4A39-97C6-624E27F767B3Q33934041-55219320-C3CD-4296-8831-20DA6A883C51Q34035588-AC11DE3B-B76E-4E91-B5E9-97FCE80551CDQ34342476-33B9AF11-BA88-4BA9-85A6-9026EB72FA69Q34983974-13F7DD3A-B5CB-48EA-B352-72816C1CAB8BQ35369634-F11BC7CC-7C58-427D-9932-166B20C78160Q35434973-7B9851A1-AF41-4D6F-8A02-FD198E2F7F3AQ35634109-33F50031-25D6-4B0A-8045-0B63FFE0EFE6Q36465271-B45124EC-35DD-470A-9CF8-33BBFCDC9ED7Q37047827-400FF32D-1C72-4A8F-AB8D-E57969260D4EQ37161516-66583296-636A-4AC6-A628-1CF9B0DB11D5Q37311326-7DE612FA-3DA5-4F10-81BA-6FF45A4E4D86Q37872038-64B75065-82C4-48E8-9124-D979FB9C751CQ38030235-E8E5F9A6-42BD-4043-ADDA-6B1A42B6E9F8Q38113421-FD8C92AF-44F2-4667-AD2B-EF87FE961960Q38206945-965C3322-6142-46A4-A05D-B6EFB3A41369Q38294894-91B10DB8-0D5C-49C3-BFB6-0C80146F4C9EQ38521537-65FADC35-2FF0-467D-84DD-1B7D452A51ABQ38777852-EAC38AAA-E371-41CD-BEFC-80A5D9C45328Q38998146-121DC292-585E-4AD9-84F7-700D22969D1AQ39433325-8ACD1B8F-37BF-4E52-830C-4E55BCC6D042Q42553554-A41EA429-7A9D-43D8-8409-29C4B128453AQ42798552-7065F0DF-996F-4375-87AD-E45FCA6F4C07Q52876094-F0F32BEE-0037-40CC-B980-427591C7210EQ53093869-7F788011-1CB6-4A40-A67D-CFCB6A46DB00Q56806670-D2344E35-2F0C-4257-9B56-B35CC9806B09Q58134046-B0AAB0AF-71ED-480B-A4BC-7607712404F2Q58277593-76AE1DD0-4E98-45D9-BD8F-5864E9EDADEBQ58596162-D0C7DBFE-C63A-4458-A20F-9117660F027F
P2860
Anti-DNA antibodies: aspects of structure and pathogenicity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Anti-DNA antibodies: aspects of structure and pathogenicity.
@ast
Anti-DNA antibodies: aspects of structure and pathogenicity.
@en
type
label
Anti-DNA antibodies: aspects of structure and pathogenicity.
@ast
Anti-DNA antibodies: aspects of structure and pathogenicity.
@en
prefLabel
Anti-DNA antibodies: aspects of structure and pathogenicity.
@ast
Anti-DNA antibodies: aspects of structure and pathogenicity.
@en
P356
P1476
Anti-DNA antibodies: aspects of structure and pathogenicity.
@en
P2093
P2888
P304
P356
10.1007/S000180300026
P577
2003-02-01T00:00:00Z